Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Climb Bio, Inc.CLYM · Entity 5064 | Director | June 05, 2026 | June 08, 2026 |
| Vor Biopharma Inc.VOR · Entity 4763 | Director | June 11, 2026 | June 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Climb Bio, Inc.
Report date June 05, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.55 · Expires 2036-06-04 | Direct | 40,000 |
Reported balance
After 2026-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 40,000 · Balance 40,000 F1: The shares subject to the option will vest on the earlier of June 5, 2027 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date. F2: Under the reporting person's arrangement with RA Capital Management, L.P. (the "Adviser"), the reporting person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The reporting person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account to the Adviser. The reporting person therefore disclaims beneficial ownership of the stock option and underlying common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest on the earlier of June 5, 2027 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date.
F2: Under the reporting person's arrangement with RA Capital Management, L.P. (the "Adviser"), the reporting person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The reporting person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account to the Adviser. The reporting person therefore disclaims beneficial ownership of the stock option and underlying common stock.
Vor Biopharma Inc.
Report date June 11, 2026 · Filed June 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.09 · Expires 2036-06-10 | Direct | 57,162 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 57,162 · Balance 57,162 F1: One thirty-sixth of the shares subject to the option shall vest and become exercisable on July 11, 2026 and each month thereafter, subject to the Reporting Person's continued service through each such vesting date. F2: Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: One thirty-sixth of the shares subject to the option shall vest and become exercisable on July 11, 2026 and each month thereafter, subject to the Reporting Person's continued service through each such vesting date.
F2: Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2026 Filed Jun 13, 2026 00:39 UTC | Vor Biopharma Inc. VOR · Entity 4763 | GrantStock option (right to buy) · Derivative | 57,162 | $0.00 Strike: $14.09 | $0.00 |
DisclosureSEC source: 0001193125-26-269994 · ownership.xml · derivative · entry 1 Levin Andrew David · CIK 0001867539 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,162 Underlying: Common stock · 57,162 shares Expires 2036-06-10 F1 · derivative.exercise_date: One thirty-sixth of the shares subject to the option shall vest and become exercisable on July 11, 2026 and each month thereafter, subject to the Reporting Person's continued service through each such vesting date. F2 · ownership.direct: Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock. Read SEC document |
| June 05, 2026 Filed Jun 8, 2026 22:42 UTC | Climb Bio, Inc. CLYM · Entity 5064 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $10.55 | $0.00 |
DisclosureSEC source: 0001193125-26-262292 · ownership.xml · derivative · entry 1 Levin Andrew David · CIK 0001867539 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2036-06-04 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 5, 2027 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date. F2 · ownership.direct: Under the reporting person's arrangement with RA Capital Management, L.P. (the "Adviser"), the reporting person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The reporting person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account to the Adviser. The reporting person therefore disclaims beneficial ownership of the stock option and underlying common stock. Read SEC document |
| December 18, 2025 Filed Dec 19, 2025 23:14 UTC | Vor Biopharma Inc. VOR · Entity 4763 | GrantStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $12.80 | $0.00 |
DisclosureSEC source: 0001867539-25-000006 · form4-12192025_111222.xml · derivative · entry 1 Levin Andrew David · CIK 0001867539 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires 2035-12-17 F1 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 36 successive equal monthly installments beginning on December 18, 2025, in each case subject to the Reporting Person's continued service as of each such date. F2 · ownership.direct: Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock. Read SEC document |
| June 04, 2025 Filed Jun 5, 2025 20:10 UTC | Climb Bio, Inc. CLYM · Entity 5064 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0000950170-25-082321 · ownership.xml · derivative · entry 1 Levin Andrew David · CIK 0001867539 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2035-06-03 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 4, 2026 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date. F2 · ownership.direct: Under the reporting person's arrangement with RA Capital Management, L.P. (the "Adviser"), the reporting person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), RA Capital Nexus Fund III, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The reporting person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund II, the Nexus Fund III, and the Account to the Adviser. The reporting person therefore disclaims beneficial ownership of the stock option and underlying common stock. Read SEC document |
| June 26, 2024 Filed Jun 28, 2024 22:09 UTC | Climb Bio, Inc. ELYM · Entity 5064 | GrantStock Option (Right To Buy) · Derivative | 10,000 | $0.00 Strike: $7.89 | $0.00 |
DisclosureSEC source: 0001415889-24-018481 · form4-06282024_100647.xml · derivative · entry 1 Levin Andrew David · CIK 0001867539 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2034-06-25 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of June 26, 2025 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date. F2 · ownership.direct: Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund II, and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock. Read SEC document |
| May 18, 2023 Filed May 22, 2023 21:02 UTC | Climb Bio, Inc. ELYM · Entity 5064 | GrantStock Option (Right To Buy) · Derivative | 10,000 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001209191-23-031509 · doc4.xml · derivative · entry 1 Levin Andrew David · CIK 0001867539 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-05-17 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of May 18, 2024 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date. F2 · ownership.direct: Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund II, and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock. Read SEC document |
| May 19, 2022 Filed Jun 1, 2022 21:07 UTC | Climb Bio, Inc. ELYM · Entity 5064 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $3.46 | $0.00 |
DisclosureSEC source: 0001209191-22-033210 · doc4.xml · derivative · entry 1 Levin Andrew David · CIK 0001867539 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-05-18 F1 · derivative.exercise_date: The shares subject to the option will vest on the earlier of May 19, 2023 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date. F2 · ownership.direct: Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund II, and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock. Read SEC document |
| August 09, 2021 Filed Aug 11, 2021 21:14 UTC | Climb Bio, Inc. ELYM · Entity 5064 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $12.50 | $0.00 |
DisclosureSEC source: 0001209191-21-050934 · doc4.xml · derivative · entry 1 Levin Andrew David · CIK 0001867539 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-08-08 F1 · derivative.exercise_date: For so long as the Reporting Person continuously provides services to the Issuer, this option will vest with respect to the shares as follows: 1/36th of the shares will vest on each monthly anniversary of August 1, 2021. F2 · ownership.direct: Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II"), and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, the Nexus Fund II, and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.